Japanese Journal of Clinical Oncology 34:86-89 (2004)
© 2004 Foundation for Promotion of Cancer Research
Comparisons of Percent Equol Producers between Prostate Cancer Patients and Controls: Case-controlled Studies of Isoflavones in Japanese, Korean and American Residents
1 Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, 2 Department of Urology, University of Kyushu, Fukuoka, 3 Department of Urology, Nara Medical School, Kashihara, Nara, 4 Department of Urology, Sapporo Medical University, School of Medicine, Sapporo, 5 Department of Urology, Iwate Medical University, School of Medicine, Morioka, 6 Department of Epidemiology, Sapporo Medical University, Hokkaido, Japan, 7 Department of Urology, Chungbuk National University Hospital, Chungbuk, 8 Department of Urology, Wonju Medical School, Yonsei University, Wonju, Korea and 9 Department of Urology, UCLA School of Medicine, Los Angeles, USA
Background: Our previous case-control study revealed that the Japanese residents in Japan could be divided into those who are able to degrade daidzein, a soybean isoflavone, to equol and those without this ability, and that the incidence of prostate cancer is higher in the latter group.
Methods: We recently conducted a similar case-control study involving not only Japanese residents in Japan but also Korean residents in Korea. The incidence of prostate cancer in Korean residents is known to be close to that of Japanese residents in Japan. On the other hand, American residents in the United States have a markedly higher incidence of prostate cancer as compared to Japanese residents in Japan.
Results: The number of subjects was 295 in Japan (133 patients and 162 controls), 122 in Korea (61 patients and 61 controls) and 45 in the United States (24 patients and 21 controls). The percentage of equol producers among patients and controls was 29% and 46% in Japan (P = 0.004) and 30% and 59% in Korea (P = 0.001), respectively. The active isoflavone level was markedly lower and the percentage of equol producers was also lower (17% for patients and 14% for controls) for Americans as compared to the Japanese and Koreans.
Conclusions: These results suggest that the ability of producing equol or equol itself is closely related to the lower incidence of prostate cancer. The results also suggest that a diet based on soybean isoflavones will be useful in preventing prostate cancer.
+ For reprints and all correspondence: Hideyuki Akaza, Department of Urology, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba-City, Ibaraki 305-8575, Japan. E-mail: akazah{at}md.tsukuba.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. R. Wikoff, A. T. Anfora, J. Liu, P. G. Schultz, S. A. Lesley, E. C. Peters, and G. Siuzdak Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites PNAS, March 10, 2009; 106(10): 3698 - 3703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhao, Z. Mao, and R. D. Brinton A Select Combination of Clinically Relevant Phytoestrogens Enhances Estrogen Receptor {beta}-Binding Selectivity and Neuroprotective Activities in Vitro and in Vivo Endocrinology, February 1, 2009; 150(2): 770 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kurahashi, M. Iwasaki, M. Inoue, S. Sasazuki, and S. Tsugane Plasma Isoflavones and Subsequent Risk of Prostate Cancer in a Nested Case-Control Study: The Japan Public Health Center J. Clin. Oncol., December 20, 2008; 26(36): 5923 - 5929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atkinson, K. M Newton, E. J A. Bowles, M. Yong, and J. W Lampe Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States Am. J. Clinical Nutrition, March 1, 2008; 87(3): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Brink, V. Coxam, S. Robins, K. Wahala, A. Cassidy, F. Branca, and on behalf of the PHYTOS Investigators Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study Am. J. Clinical Nutrition, March 1, 2008; 87(3): 761 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bolca, S. Possemiers, A. Herregat, I. Huybrechts, A. Heyerick, S. De Vriese, M. Verbruggen, H. Depypere, D. De Keukeleire, M. Bracke, et al. Microbial and Dietary Factors Are Associated with the Equol Producer Phenotype in Healthy Postmenopausal Women J. Nutr., October 1, 2007; 137(10): 2242 - 2246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Clerici, K. D. R. Setchell, P. M. Battezzati, M. Pirro, V. Giuliano, S. Asciutti, D. Castellani, E. Nardi, G. Sabatino, S. Orlandi, et al. Pasta Naturally Enriched with Isoflavone Aglycons from Soy Germ Reduces Serum Lipids and Improves Markers of Cardiovascular Risk J. Nutr., October 1, 2007; 137(10): 2270 - 2278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C.S. Talbot, R. M. Ogborne, T. Dadd, H. Adlercreutz, G. Barnard, S. Bugel, F. Kohen, S. Marlin, J. Piron, A. Cassidy, et al. Monoclonal Antibody-Based Time-Resolved Fluorescence Immunoassays for Daidzein, Genistein, and Equol in Blood and Urine: Application to the Isoheart Intervention Study Clin. Chem., April 1, 2007; 53(4): 748 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rafailov, S. Cammack, B. A. Stone, and A. E. Katz The Role of Zyflamend, an Herbal Anti-inflammatory, as a Potential Chemopreventive Agent Against Prostate Cancer: A Case Report Integr Cancer Ther, March 1, 2007; 6(1): 74 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Raschke, I. R. Rowland, P. J. Magee, and B. L. Pool-Zobel Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress Carcinogenesis, November 1, 2006; 27(11): 2322 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. R. Setchell and S. J. Cole Method of Defining Equol-Producer Status and Its Frequency among Vegetarians J. Nutr., August 1, 2006; 136(8): 2188 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Song, C. Atkinson, C. L. Frankenfeld, T. Jokela, K. Wahala, W. K. Thomas, and J. W. Lampe Prevalence of Daidzein-Metabolizing Phenotypes Differs between Caucasian and Korean American Women and Girls J. Nutr., May 1, 2006; 136(5): 1347 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Decroos, E. Eeckhaut, S. Possemiers, and W. Verstraete Administration of Equol-Producing Bacteria Alters the Equol Production Status in the Simulator of the Gastrointestinal Microbial Ecosystem (SHIME) J. Nutr., April 1, 2006; 136(4): 946 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ma, D. Chiriboga, B. C. Olendzki, R. Nicolosi, P. A. Merriam, and I. S. Ockene Effect of Soy Protein Containing Isoflavones on Blood Lipids in Moderately Hypercholesterolemic Adults: A Randomized Controlled Trial J. Am. Coll. Nutr., August 1, 2005; 24(4): 275 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Setchell, C. Clerici, E. D Lephart, S. J Cole, C. Heenan, D. Castellani, B. E Wolfe, L. Nechemias-Zimmer, N. M Brown, T. D Lund, et al. S-Equol, a potent ligand for estrogen receptor {beta}, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1072 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Atkinson, C. L. Frankenfeld, and J. W. Lampe Gut Bacterial Metabolism of the Soy Isoflavone Daidzein: Exploring the Relevance to Human Health Experimental Biology and Medicine, March 1, 2005; 230(3): 155 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-L. Wang, H.-G. Hur, J. H. Lee, K. T. Kim, and S.-I. Kim Enantioselective Synthesis of S-Equol from Dihydrodaidzein by a Newly Isolated Anaerobic Human Intestinal Bacterium Appl. Envir. Microbiol., January 1, 2005; 71(1): 214 - 219. [Abstract] [Full Text] [PDF]
|
|